XBiotech, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Austin TX United States (2007)

Organization Overview

First Clinical Trial
2010
NCT01021072
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

XBiotech, Inc. | XBiotech USA, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

xilonix (4 trials)

Drugs in Phase 2 Trials (5)

bermekimab (4 trials)

methotrexate (1 trial)

natrunix (3 trials)

omodenbamab (1 trial)

t2-18c3 (7 trials)

Drugs in Phase 1 Trials (1)

hutrukin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 2)

Bacteremia (Phase 2)

Cachexia (Phase 3)

Colorectal Neoplasms (Phase 3)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Eczema (Phase 2)

Hidradenitis (Phase 2)

Hidradenitis Suppurativa (Phase 2)

Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 1)

Psoriasis (Phase 2)

Pyoderma (Phase 2)

Pyoderma Gangrenosum (Phase 2)

Wasting Syndrome (Phase 1)

Weight Loss (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial APIs: 7